Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine

▴ Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine
“These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease."

Merck, known as MSD outside the United States and Canada, today announced the company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for licensure of V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older. The company awaits acceptance of the submissions by the U.S. and European regulatory authorities.

“For more than a century, Merck inventors have developed vaccines that help tackle some of society’s biggest public health challenges, and that heritage is reflected today in our pneumococcal vaccine portfolio,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease.”

The regulatory applications for licensure of V114 include results from Phase 2 and Phase 3 clinical studies in a variety of adult populations, including healthy adults and those at increased risk, such as adults with chronic medical conditions, adults with HIV, and those 65 years of age and older.

Tags : #LatestPharmaNewsNov23 #LatestMerckNewsNov23 #TreatmentforPneumococcalDisease

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025
India’s Newborns Are Dying from Sepsis And No One Is Talking About ItFebruary 27, 2025
Did the Government Force Covid Vaccines Without Responsibility? The Supreme Court Thinks SoFebruary 26, 2025
The Inequality of Survival: Why Some Women Die While Others LiveFebruary 26, 2025
The Corporate Invasion of Indian Hospitals: What It Means for YouFebruary 26, 2025
5 Simple Daily Habits to Keep Your Joints Healthy and Pain-FreeFebruary 25, 2025
Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in IndiaFebruary 25, 2025
With only 70 months left to end AIDS why is the urgency missing?February 25, 2025
Drenched in Oil: Is India Cooking Its Way to an Obesity Epidemic?February 25, 2025
Transforming Education: How Online Learning Platforms are Reshaping Study Material for Board and Competitive ExamsFebruary 24, 2025
February 24, 2025
The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West AfricaFebruary 24, 2025
The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing SystemFebruary 24, 2025
From Science Fiction to Reality: AI Now Detects Blindness Before It StartsFebruary 24, 2025
Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025